

Registered number
05480714

Dawat Pharma Limited

Report and Accounts

31 March 2020

Dawat Pharma Limited**Registered number:** 05480714**Balance Sheet****as at 31 March 2020**

	Notes	2020 £	2019 £
Fixed assets			
Tangible assets	2	4,201	4,036
Investments	3	125,000	125,000
		<u>129,201</u>	<u>129,036</u>
Current assets			
Debtors	4	12,539	335
Cash at bank and in hand		81,905	70,032
		<u>94,444</u>	<u>70,367</u>
Creditors: amounts falling due within one year	5	(103,160)	(120,831)
Net current liabilities		<u>(8,716)</u>	<u>(50,464)</u>
Net assets		<u>120,485</u>	<u>78,572</u>
Capital and reserves			
Called up share capital		1,000	1,000
Profit and loss account		119,485	77,572
Shareholders' funds		<u>120,485</u>	<u>78,572</u>

The director is satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit in accordance with section 476 of the Act.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.

Tanveer Ahmed

Director

Approved by the board on 25 April 2020

Dawat Pharma Limited
Notes to the Accounts
for the year ended 31 March 2020

1 Accounting policies

Turnover

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

Tangible fixed assets

Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:

Fixtures, fittings, tools and equipment	15% reducing balance method
---	-----------------------------

Investments

Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.

2 Tangible fixed assets

	FF and equipment etc £
Cost	
At 1 April 2019	10,470
Additions	800
At 31 March 2020	<u>11,270</u>
Depreciation	
At 1 April 2019	6,434
Charge for the year	635
At 31 March 2020	<u>7,069</u>
Net book value	
At 31 March 2020	<u>4,201</u>
At 31 March 2019	4,036

3 Investments

	Other investments £
Cost	
At 1 April 2019	125,000
At 31 March 2020	<u>125,000</u>

4 Debtors	2020 £	2019 £
Trade debtors	12,096	-
Paye Ctrl	443	335
	<u>12,539</u>	<u>335</u>

5 Creditors: amounts falling due within one year	2020 £	2019 £
Trade creditors	70	60
Directors' account	92,105	113,733
Accruals	650	650
Vat payable	10,335	6,388
	<u>103,160</u>	<u>120,831</u>

6 Other information

Dawat Pharma Limited is a private company limited by shares and incorporated in England. Its registered office is:

103 Broadway West
Walsall
West Midlands
WS1 4DW

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.